证券代码：600201 证券简称：生物股份 公告编号：临2026-004 金宇生物技术股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 类型：股份有限公司（上市、自然人投资或控股） 住所：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大街 1 号 法定代表人：张翀宇 注册资本：壹拾壹亿壹仟壹佰柒拾肆万柒仟捌佰贰拾陆元（人民币元） 成立日期：1993 年 03 月 13 日 经营范围：兽用生物药品制造和销售；兽用化学药品制剂制造和销售；化学 试剂和助剂制造和销售；生物药品制剂制造和销售；生物技术开发、转让、咨询 服务；先进医疗设备及器械制造和销售；货物进出口、技术进出口；物业管理。 特此公告。 金宇生物技术股份有限公司（以下简称"公司"）第十一届董事会第十八次 会议和 2024 年年度股东大会审议通过了《关于修订<公司章程>及其他制度的议案》， 具体内容详见公司披露在上海证券交易所网站的《金宇生物技术股份有限公司关 于修订<公司章程>及其他制度的公告》（公告编号：临 2025-02 ...

Core Viewpoint - The actual controller of Baolingbao Biotech Co., Ltd., Mr. Dai Sichong, has expanded the shareholding plan to include a new entity, CEDARWALK BIOTECH HONG KONG LIMITED, to facilitate the acquisition of shares in the company [1][2]. Summary by Sections Shareholding Plan Overview - The original plan was to increase shareholding by 18,488,369 shares (5% of total shares) to a maximum of 36,976,738 shares (10% of total shares) starting from October 8, 2024, for a period of six months [1]. - The plan has been extended by 12 months, now set to conclude on April 7, 2026, while other details remain unchanged [2]. Addition of New Entity - CEDARWALK BIOTECH HONG KONG LIMITED has been added as a new entity to the shareholding plan, which is controlled by Mr. Dai Sichong [2][3]. - This entity will operate through a specific investment account managed by Guotou Securities Asset Management (Hong Kong) [2]. Shareholding Changes - As of February 4, 2026, the cumulative shares acquired by Shenzhen Songjing Investment Partnership and CEDARWALK BIOTECH HONG KONG LIMITED amount to 6,375,700 shares, representing 1.67531% of the total shares [3]. - The total shares acquired from November 2025 to February 2026 reached 5,076,300 shares, increasing the combined holding to 13.99607% [4]. Compliance and Commitments - The shareholding plan complies with relevant laws and regulations, ensuring that it does not affect the company's listing status or control [6]. - CEDARWALK BIOTECH HONG KONG LIMITED has committed to not reducing its holdings for six months post-acquisition [6].

Core Insights - The 2026 Central Document emphasizes the transition from "ensuring quantity" to "improving quality" in agriculture, marking the beginning of the 14th Five-Year Plan [2][27] - The document sets a target for grain production at approximately 1.4 trillion jin (around 700 million tons) and initiates a new round of actions to enhance grain production capacity [2][27] - The focus shifts to "new agricultural productivity," indicating a transition from resource input to technology-driven development [2][27] Policy Highlights - The document introduces a "bottom line" and "action" plan, ensuring stable grain production and enhancing agricultural capacity, which will create sustained demand in the planting industry [2][27] - It upgrades the policy on pig production from "monitoring" to "comprehensive capacity regulation," aiming to balance supply and demand in the pork market [2][28] - The document proposes a financial mechanism to support agriculture, utilizing special bonds and long-term bonds to lower financing costs for agricultural enterprises [2][28] Industry Confidence - The document reflects four types of confidence in agriculture: technological confidence, trade confidence, subject confidence, and strategic confidence, which collectively aim to strengthen the agricultural sector [5][30] - The emphasis on technological advancements and international competitiveness in agriculture is expected to benefit leading agricultural enterprises [5][30] ETF Insights - The Agricultural, Animal Husbandry, and Fishery ETF (159275) tracks the CSI Agricultural Index, with its top holdings aligned with the key areas highlighted in the document [6][31] - The ETF's top ten holdings include major companies in pig farming and feed production, which are expected to benefit from the new policies [6][31] - The ETF is viewed as a strategic investment tool for gaining exposure to the core agricultural industry chain, especially at a time when the industry cycle is at a low point [34][45] Market Performance - Following the release of the document, the Agricultural ETF saw a 1.12% increase, indicating rising investor interest [19][40] - Key stocks within the ETF, such as Haida Group and Muyuan Foods, experienced notable price increases, reflecting heightened market attention [19][42] Future Outlook - Short-term policy benefits and seasonal trends may lead to a surge in ETF performance, while mid-term prospects depend on pig prices and capacity adjustments [44][45] - Long-term agricultural modernization is a national strategy, with leading companies expected to capture more market share as industry concentration increases [45][46]

Core Viewpoint - The animal health sector experienced a decline of 0.95% on February 4, with leading company BioShares falling significantly, while the overall market indices showed slight gains [1][2]. Market Performance - The Shanghai Composite Index closed at 4102.2, up by 0.85% - The Shenzhen Component Index closed at 14156.27, up by 0.21% [1]. Individual Stock Performance - The following stocks in the animal health sector showed notable price changes: - Yongshun Biological: Closed at 9.55, up by 1.27% with a trading volume of 42,400 shares and a turnover of 40.27 million yuan - Zhongmu Co.: Closed at 8.00, up by 1.14% with a trading volume of 139,400 shares and a turnover of 111 million yuan - Jinhai Biological: Closed at 6.34, up by 0.79% with a trading volume of 112,700 shares and a turnover of 70.98 million yuan - BioShares: Closed at 15.88, down by 3.29% with a trading volume of 534,100 shares and a turnover of 84.5 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 184 million yuan from institutional investors, while retail investors contributed a net inflow of 143 million yuan [2][3]. - The following stocks had significant capital flow: - Qudongli: Net inflow of 2.30 million yuan from institutional investors, but a net outflow of 1.89 million yuan from retail investors - Zhongmu Co.: Net inflow of 1.99 million yuan from institutional investors, with a net outflow of 6.49 million yuan from retail investors [3].

Group 1 - The core point of the article is that Inner Mongolia Jinyu Biological Holdings Co., Ltd., a shareholder holding more than 5% of the shares, has released 18,600,000 shares of the company's unrestricted circulating shares from pledge as of February 2, 2026, which accounts for 14.82% of its holdings [2]

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

金宇生物技术股份有限公司 关于股东股份解除质押的公告 证券代码：600201 证券简称：生物股份 公告编号：临 2026-003 生物控股原质押给西藏信托有限公司的本公司 18,600,000 股无限售流通股 股票已于 2026 年 2 月 2 日解除质押，并已办理完成上述股票解除质押的相关手续。 具体情况如下： | 股东名称 | 内蒙古金宇生物控股有限公司 | | --- | --- | | 本次解质（解冻）股份 | 18,600,000 股 | | 占其所持股份比例 | 14.82% | | 占公司总股本比例 | 1.67% | | 解质（解冻）时间 | 2026 年 2 月 2 日 | | 持股数量 | 125,510,800 股 | | 持股比例 | 11.29% | | 剩余被质押（被冻结）股份数量 | 15,820,000 股 | | --- | --- | | 剩余被质押（被冻结）股份数量占其所 | 12.60% | | 持股份比例 | | | 剩余被质押（被冻结）股份数量占公司 | 1.42% | | 总股本比例 | | 上述解除质押股份暂无后续质押计划。未来如有变动，公司将按照相关法律 法规 ...

Core Viewpoint - The company announced that its major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., has released a pledge on 18.6 million shares, which represents 14.82% of its holdings and 1.67% of the company's total share capital [1] Group 1 - After the release of the pledge, the shareholder holds 126 million shares, accounting for 11.29% of the total share capital [1] - The remaining pledged shares amount to 15.82 million, which is 12.60% of the shareholder's total holdings and 1.42% of the company's total share capital [1] - The combined holdings of Jinyu Biological Holdings and its concerted parties total 155 million shares, representing 13.91% of the total share capital, with a cumulative pledge of 15.82 million shares, which is 10.23% of the combined holdings [1]

Group 1 - The company disclosed a research reception announcement, indicating that it hosted 28 institutions including Ruifeng Fund and CITIC Securities for a research meeting on January 30, 2026 [1] - The latest stock price of the company is 16.28 yuan, down 1.77 yuan or 9.81% from the previous trading day's closing price, with a total market value of 18.099 billion yuan [1] - The company operates in the pesticide and veterinary drug industry, with a rolling average industry P/E ratio of 47.77 times and a median of 27.11 times, while the company's P/E ratio stands at 179.63 times, ranking 32nd in the industry [1] Group 2 - The clinical trial progress of the African swine fever vaccine is on track, having obtained clinical approval in July 2025, started field trials in October, and completed the first challenge trial on January 23, 2026, meeting interim evaluation requirements [1] - The company plans to initiate the second round of challenge trials in early April 2026 and complete all clinical trial data collection and analysis by June [1] - The African swine fever vaccine has significant competitive advantages, including high safety and protection rates, and has completed large-scale immunization experiments involving 10,000 pigs [1] Group 3 - The company is actively advancing its international strategy, having reached cooperation intentions with relevant departments and enterprises in Vietnam to promote the trial and registration of the African swine fever subunit vaccine [2] - The mRNA vaccine for feline infectious peritonitis, a globally pioneering product, received clinical trial approval in July 2025, with a protection rate exceeding 80%, and is expected to be launched in 2028 [2] - As of September 30, 2025, the company had 49,033 shareholders, a decrease of 5,873 from the previous count, with an average holding value of 369,100 yuan and an average holding quantity of 22,700 shares [2]

证券之星消息，2月2日动物保健板块较上一交易日下跌4.9%，生物股份领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002141 | 后丰控股 | 3.98 | 0.76% | 29.51万 | 1.16亿 | | 002868 | *ST绿康 | 35.53 | -0.73% | 1.21万 | 4321.94万 | | 603566 | 普莱柯 | 13.72 | -1.15% | 7.48万 | 1.03亿 | | 688098 | 申联生物 | 9.36 | -1.78% | 4.23万 | 4019.07万 | | 688526 | 科前生物 | 15.98 | -3.33% | 4.70万 | 7617.62万 | | 600195 | 中牧股份 | 7.88 | -3.55% | 24.23万 | 1.95亿 | | 002688 | 金河生物 | ...